Cargando…

Blood lactate in mild and moderate ARDS secondary to SARS COV 2

BACKGROUND AND OBJECTIVES: Elevated blood lactate levels are associated with poor outcome in several critical conditions. Patients with SARS-CoV-2 rarely develop hyperlactatemia. The purpose of this study is to evaluate the trend of lactatemia in patients affected by mild/moderate SARS-Co V-2-ARDS a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagano, A., Porta, G., Bosso, G., Allegorico, E., Serra, C., Mercurio, V., Sansone, G., Orefice, S., Numis, F.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869639/
https://www.ncbi.nlm.nih.gov/pubmed/36731159
http://dx.doi.org/10.1016/j.ajem.2023.01.032
_version_ 1784876810695081984
author Pagano, A.
Porta, G.
Bosso, G.
Allegorico, E.
Serra, C.
Mercurio, V.
Sansone, G.
Orefice, S.
Numis, F.G.
author_facet Pagano, A.
Porta, G.
Bosso, G.
Allegorico, E.
Serra, C.
Mercurio, V.
Sansone, G.
Orefice, S.
Numis, F.G.
author_sort Pagano, A.
collection PubMed
description BACKGROUND AND OBJECTIVES: Elevated blood lactate levels are associated with poor outcome in several critical conditions. Patients with SARS-CoV-2 rarely develop hyperlactatemia. The purpose of this study is to evaluate the trend of lactatemia in patients affected by mild/moderate SARS-Co V-2-ARDS and if it affected prognosis. METHODS: We analyzed blood lactate levels in thirty-eight patients with severe SARS-CoV-2 infection admitted to COVID Care Unit of Santa Maria delle Grazie Hospital, Pozzuoli. RESULTS: Twenty patients survived and were discharged at home and 18 patients died. Despite severe hypoxia that affected all patients enrolled, T0 lactate was within normal values. All survivors showed a significant increase in lactate concentration the day prior to clinical improvement. In not-survivors levels of lactate did not increase significantly. CONCLUSION: In our study, patients who survive SARS CoV-2 ARDS have a fleeting increase in lactate, which precedes clinical improvement by one day.
format Online
Article
Text
id pubmed-9869639
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-98696392023-01-23 Blood lactate in mild and moderate ARDS secondary to SARS COV 2 Pagano, A. Porta, G. Bosso, G. Allegorico, E. Serra, C. Mercurio, V. Sansone, G. Orefice, S. Numis, F.G. Am J Emerg Med Article BACKGROUND AND OBJECTIVES: Elevated blood lactate levels are associated with poor outcome in several critical conditions. Patients with SARS-CoV-2 rarely develop hyperlactatemia. The purpose of this study is to evaluate the trend of lactatemia in patients affected by mild/moderate SARS-Co V-2-ARDS and if it affected prognosis. METHODS: We analyzed blood lactate levels in thirty-eight patients with severe SARS-CoV-2 infection admitted to COVID Care Unit of Santa Maria delle Grazie Hospital, Pozzuoli. RESULTS: Twenty patients survived and were discharged at home and 18 patients died. Despite severe hypoxia that affected all patients enrolled, T0 lactate was within normal values. All survivors showed a significant increase in lactate concentration the day prior to clinical improvement. In not-survivors levels of lactate did not increase significantly. CONCLUSION: In our study, patients who survive SARS CoV-2 ARDS have a fleeting increase in lactate, which precedes clinical improvement by one day. Elsevier Inc. 2023-04 2023-01-23 /pmc/articles/PMC9869639/ /pubmed/36731159 http://dx.doi.org/10.1016/j.ajem.2023.01.032 Text en © 2023 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Pagano, A.
Porta, G.
Bosso, G.
Allegorico, E.
Serra, C.
Mercurio, V.
Sansone, G.
Orefice, S.
Numis, F.G.
Blood lactate in mild and moderate ARDS secondary to SARS COV 2
title Blood lactate in mild and moderate ARDS secondary to SARS COV 2
title_full Blood lactate in mild and moderate ARDS secondary to SARS COV 2
title_fullStr Blood lactate in mild and moderate ARDS secondary to SARS COV 2
title_full_unstemmed Blood lactate in mild and moderate ARDS secondary to SARS COV 2
title_short Blood lactate in mild and moderate ARDS secondary to SARS COV 2
title_sort blood lactate in mild and moderate ards secondary to sars cov 2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869639/
https://www.ncbi.nlm.nih.gov/pubmed/36731159
http://dx.doi.org/10.1016/j.ajem.2023.01.032
work_keys_str_mv AT paganoa bloodlactateinmildandmoderateardssecondarytosarscov2
AT portag bloodlactateinmildandmoderateardssecondarytosarscov2
AT bossog bloodlactateinmildandmoderateardssecondarytosarscov2
AT allegoricoe bloodlactateinmildandmoderateardssecondarytosarscov2
AT serrac bloodlactateinmildandmoderateardssecondarytosarscov2
AT mercuriov bloodlactateinmildandmoderateardssecondarytosarscov2
AT sansoneg bloodlactateinmildandmoderateardssecondarytosarscov2
AT orefices bloodlactateinmildandmoderateardssecondarytosarscov2
AT numisfg bloodlactateinmildandmoderateardssecondarytosarscov2